Acumen shares surge 13.60% after-hours as BTIG raises price target to $7 from $4 with Buy rating.

Acumen Pharmaceuticals (ABOS) surged 13.6% in after-hours trading, driven by a combination of clinical progress and an analyst upgrade. The company announced dosing the first participant in the open-label extension of its Phase 2 ALTITUDE-AD trial for sabirnetug in Alzheimer’s disease, reinforcing momentum toward a late-2026 data readout. Simultaneously, BTIG raised its price target from $4 to $7, maintaining a "Buy" rating, signaling renewed confidence in the stock’s potential. While insider tax-related sales were disclosed, analysts characterized them as routine and unrelated to the company’s clinical thesis. The dual catalysts of trial advancement and improved analyst sentiment aligned with the sharp post-market rally, highlighting investor optimism about Acumen’s Alzheimer’s program and its path toward meaningful data milestones.